Drug updated on 4/18/2024
| Dosage Form | Injection (intramuscular; 100 units/vial) |
| Drug Class | Acetylcholine release inhibitors and neuromuscular blocking agents |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.
Summary
- PrabotulinumtoxinA-xvfs (Jeuveau) is recommended for the temporary reduction of moderate to severe glabellar lines resulting from corrugator and/or procerus muscle activity in adult patients. Studies based on phase II and III clinical trials have shown that Jeuveau significantly improves these conditions, with 67.5% and 70.4% of participants achieving more than a 2-point enhancement on the Glabellar Line Scale at maximum frown from the baseline.
- Two systematic reviews/meta-analyses compared Jeuveau with other botulinum toxin type A products for managing glabellar lines.
- When evaluated against placebo groups, all botulinum toxin products reviewed showed a higher success rate by week four as assessed by participants or evaluators; however, Jeuveau exhibited notably higher response rates compared to these treatments.
- The safety profile information suggests that Jeuveau is well tolerated in all studies, with no major adverse events reported shortly after treatment. This indicates a favorable safety profile in comparison to other Botulinum Toxin Type A products, which may present an increased risk of significant adverse events such as ptosis.
- The studies primarily focused on adult patients aged between 18-65 years with moderate-to-severe glabella lines; a majority of the study participants were female, identifying this demographic as the primary group for these treatments. However, specific subgroup analyses based on age or gender are not detailed.
- While both studies highlight a robust efficacy profile comparable among various botulinum toxin type A products, including Jeuveau, there is mention of a difference in safety among the drugs. Therefore, future direct comparisons and evaluations of long-term outcomes would be beneficial, especially concerning diverse subgroups within the adult population.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Jeuveau (prabotulinumtoxinA-xvfs) Prescribing Information. | 2020 | Evolus Inc., Newport Beach, CA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Botulinum toxin type A for facial wrinkles. | 2021 | The Cochrane Database of Systematic Reviews |
| PrabotulinumtoxinA-xvfs for the treatment of moderate-to-severe glabellar lines. | 2021 | Annals of Pharmacotherapy |